RxDoctor Payments Data

Jessica Shen, MD

Otolaryngology · Chevy Chase, MDNPI 1306044086

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 27.5% of the total. 2025 is the largest year on record at $977, 2.2 times the $451 reported in 2019.

$3,552in general payments, 2019–2025

Across 132 payments — averaging $26.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$977
  • GSK$718
  • Sanofi$665
  • Optinose US, Inc.$251
  • Acclarent, Inc$166
  • Medtronic$161
  • plus $615 from 17 others

What the payments were for

  • Food & beverage$3,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,552 in reported general payments places this provider in the 80th percentile of 222 otolaryngology providers in Maryland.

See all otolaryngology providers in Maryland

Medicare billing

Part B allowed, 2024
$121,840
Medicare patients
623
Services billed
1,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluocinolone Acetonide Oil61$3,254
Olopatadine Hcl21$2,752
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth15$1,954
Ipratropium Bromide45$1,492
Azelastine-FluticasoneAzelastine/Fluticasone18$1,263
Azelastine Hcl27$1,195
Fluticasone Propionate30$473
Famotidine39$452
Ofloxacin13$336
Cefdinir12$191
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid12$146
Pantoprazole Sodium15$131
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$85
Mupirocin11$64
Prednisone16$63

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →